仅骨转移HR+/HER2-转移性乳腺癌CDK4/6i治疗中内脏转化的基线变量分析
这项多中心回顾性队列纳入692例接受CDK4/6抑制剂联合内分泌治疗作为一线或二线的仅骨转移HR+/HER2-转移性乳腺癌患者,中位随访31个月,23.4%发生内脏转化。孕激素受体(PR)表达是最稳定的肿瘤生物学相关因素,但单独预测性能有限。
要点
- 仅骨转移HR+/HER2-转移性乳腺癌CDK4/6i治疗中,23.4%发生内脏转化,中位转化时间17.0个月。
- PR表达每增加10个百分点,内脏转化风险降低(sHR 0.929,95%CI 0.889-0.971,p=0.0012)。
- PR单独预测内脏转化的24个月IPCW AUC仅0.585,个体层面临床效用有限。
核心结论
- 广泛基线变量分析确定PR表达是内脏转化最可重复的肿瘤生物学相关因素,但单独预测性能有限。
研究设计与样本
- 多中心回顾性队列纳入692例接受哌柏西利、瑞波西利或阿贝西利联合内分泌治疗作为一线或二线的仅骨转移HR+/HER2-转移性乳腺癌患者,来自24个意大利中心。
- 内脏转化在竞争风险框架中分析,以骨骼进展或未发生内脏转化前的死亡为竞争事件。
- 评估18个基线候选预测因子,采用Fine-Gray模型、岭惩罚、bootstrap稳定性评估和病因特异性Cox敏感性分析。
主要发现
- 中位随访31个月,162例(23.4%)发生内脏转化,中位转化时间17.0个月。
- 12、24和36个月累积发生率分别为8.8%、17.5%和24.5%;内脏转化后中位总生存为18.0个月。
- PR表达是最稳定的肿瘤生物学相关因素,在500次bootstrap重采样中符号完全一致且中位绝对系数秩为1。
- 在相互调整的Fine-Gray模型中,PR表达较高与内脏转化风险较低相关(每增加10个百分点sHR 0.929;95%CI 0.889-0.971;p=0.0012),补充分析方向一致。
- PR单独预测性能中等(24个月IPCW AUC 0.585;Brier评分0.142;IPA 1.1%;O:E 1.00),限制个体层面临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bone-only HR+/HER2 - metastatic breast cancer generally has a favourable prognosis, but some patients develop visceral metastases. We aimed to quantify visceral conversion and identify reproducible baseline correlates during CDK4/6 inhibitor (CDK4/6i) therapy. METHODS: This multicentre retrospective cohort included 692 patients treated with palbociclib, ribociclib, or abemaciclib plus endocrine therapy as first- or second-line treatment across 24 Italian centres. Visceral conversion was analysed in a competing-risks framework, with skeletal progression or death without prior visceral conversion as competing events. Eighteen baseline candidate predictors derived from a 35-variable dataset were evaluated using Fine-Gray modelling, ridge penalisation, bootstrap stability assessment, and cause-specific Cox sensitivity analyses. RESULTS: Over a median follow-up of 31 months, 162 patients (23.4%) developed visceral conversion after a median of 17.0 months. Cumulative incidence was 8.8%, 17.5%, and 24.5% at 12, 24, and 36 months, respectively; median overall survival after visceral conversion was 18.0 months. Progesterone receptor (PR) expression was the most stable tumour-biological correlate, with complete sign concordance and a median absolute coefficient rank of 1 across 500 bootstrap resamples. In the mutually adjusted Fine-Gray model, higher PR expression was associated with lower visceral-conversion risk (sHR per 10-percentage-point increase, 0.929; 95% CI, 0.889-0.971; p = 0.0012), with consistent direction across complementary analyses. However, stand-alone PR prediction remained modest (24-month IPCW AUC, 0.585; Brier score, 0.142; IPA, 1.1%; O:E, 1.00), limiting individual-level clinical utility. CONCLUSIONS: Broad baseline-variable profiling identified PR expression as the most reproducible tumour-biological correlate of visceral conversion, although its stand-alone predictive performance was modest.
引用
- Scafetta R, Troiano R, Guarino A, et al. Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors. Eur J Cancer. 2026. PMID: 42685569. doi:10.1016/j.ejca.2026.117019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。